Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s ...

Drs Uzzo, Chung, and Croll of Fox Chase Cancer Center at Temple University Health discuss top presentations from the ASCO Genitourinary Cancers Symposium 2026. The American Society of Clinical ...

Oncology Media Relations   Oncology_media_relations@its.jnj.com     Investor contact: Jess Margevich investor-relations@its.jnj.com ...

Well, enGene is a unique company with unique technology at actually a really unique time, right? So our technology is called the DDX pl ...

It is used both to treat tumours and to help clinicians determine whether they are cancerous, as well as their grade and ...

Since joining Driscoll in 2024, he has expanded pediatric urology offerings, including new technologies that enable faster ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

The SWOG S1602 trial ( NCT03091660) evaluated the noninferiority of the Tokyo versus TICE BCG strains, as well as testing the superiority of T cell priming with intradermal BC before intravesical ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

The Urocross ® Expander System is designed to remodel the obstructed prostatic urethra through a minimally invasive cystoscopy procedure using a non-permanent, intentionally retrievable implant. The ...

After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...